257 related articles for article (PubMed ID: 2935857)
1. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
[TBL] [Abstract][Full Text] [Related]
2. Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study.
Charhon SA; Chavassieux P; Boivin G; Parisien M; Chapuy MC; Traeger J; Meunier PJ
Clin Sci (Lond); 1987 Aug; 73(2):227-34. PubMed ID: 3652627
[TBL] [Abstract][Full Text] [Related]
3. The use of intravenous and intraperitoneal desferrioxamine in aluminium osteomalacia.
O'Brien AA; McParland C; Keogh JA
Nephrol Dial Transplant; 1987; 2(2):117-9. PubMed ID: 3112649
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
McCarthy JT; Milliner DS; Johnson WJ
Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
[TBL] [Abstract][Full Text] [Related]
5. Changes in bone histology after treatment with desferrioxamine.
Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
[No Abstract] [Full Text] [Related]
6. Treatment of dialysis osteomalacia with desferrioxamine.
Brown DJ; Dawborn JK; Ham KN; Xipell JM
Lancet; 1982 Aug; 2(8294):343-5. PubMed ID: 6124756
[TBL] [Abstract][Full Text] [Related]
7. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
[No Abstract] [Full Text] [Related]
8. Aluminum-related osteomalacia: clinical and histological improvement following treatment with desferrioxamine (DFO).
Rapoport J; Chaimovitz C; Abulfil A; Mostovlavsky M; Gazit D; Bab I
Isr J Med Sci; 1987 Dec; 23(12):1242-6. PubMed ID: 3440748
[TBL] [Abstract][Full Text] [Related]
9. Aluminum-related osteomalacia in renal-failure patients.
Vick KE; Johnson CA
Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
[TBL] [Abstract][Full Text] [Related]
10. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
[TBL] [Abstract][Full Text] [Related]
11. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
Warady BA; Ford DM; Gaston CE; Sedman AB; Huffer WE; Lum GM
Pediatrics; 1986 Oct; 78(4):651-5. PubMed ID: 3763276
[TBL] [Abstract][Full Text] [Related]
12. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease.
Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; van Hooff I; Dratwa M; Verbeelen D
Clin Nephrol; 1985 Nov; 24(5):237-41. PubMed ID: 4075595
[TBL] [Abstract][Full Text] [Related]
13. [Osteomalacia induced by aluminum in a patient under chronic hemodialysis: successful treatment with desferrioxamine].
Espinoza O; Gehrung E; Roessler E; Katz E; Pérez A; Delmastro J
Rev Med Chil; 1986 Sep; 114(9):867-71. PubMed ID: 3575972
[No Abstract] [Full Text] [Related]
14. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease.
Felsenfeld AJ; Rodriguez M; Coleman M; Ross D; Llach F
Kidney Int; 1989 Jun; 35(6):1371-8. PubMed ID: 2770115
[TBL] [Abstract][Full Text] [Related]
15. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
Hodsman AB; Hood SA; Brown P; Cordy PE
J Lab Clin Med; 1985 Dec; 106(6):674-81. PubMed ID: 4067379
[TBL] [Abstract][Full Text] [Related]
16. Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine.
Mudde AH; Roodvoets AP; Van Groningen K
Neth J Med; 1985; 28(1):6-11. PubMed ID: 3974771
[No Abstract] [Full Text] [Related]
17. Fracture healing with deferoxamine therapy in a patient with aluminum-associated osteomalacia.
Phelps KR; Einhorn TA; Vigorita VJ; Lundin AP; Friedman EA
ASAIO Trans; 1986; 32(1):198-200. PubMed ID: 3778712
[No Abstract] [Full Text] [Related]
18. Clinical and biochemical features of aluminum-related bone disease.
Ihle BU; Becker GJ; Kincaid-Smith PS
Kidney Int Suppl; 1986 Feb; 18():S80-6. PubMed ID: 3458003
[No Abstract] [Full Text] [Related]
19. Treatment of fracturing renal osteodystrophy by desferrioxamine.
Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
[TBL] [Abstract][Full Text] [Related]
20. [Aluminum in chronic renal failure].
Głuszek J; Adamczak H
Rocz Panstw Zakl Hig; 1993; 44(1):43-8. PubMed ID: 8235341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
